Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of umbilical cord mesenchymal stem cells in preparation of medicine for treating novel coronal pneumonia

A technology of mesenchymal stem cells and umbilical cord, which is applied in the application field of umbilical cord mesenchymal stem cells in the preparation of drugs for the treatment of new coronary pneumonia, can solve problems such as the incomplete understanding of the pathogenesis, and achieve the relief of acute respiratory distress syndrome, pulmonary edema, The effect of reducing the fatality rate

Pending Publication Date: 2020-06-19
云南雅盛医疗科技有限公司
View PDF4 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] After 2019-nCoV infection with pneumonia, some patients will develop severe and critical illness, and its pathogenesis is not yet fully understood
Therefore, although MSCs have no direct antiviral effect and may be infected by the virus themselves, the infusion of healthy MSCs may improve the therapeutic effect of antiviral drugs by remodeling the patient's immune system

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of umbilical cord mesenchymal stem cells in preparation of medicine for treating novel coronal pneumonia
  • Application of umbilical cord mesenchymal stem cells in preparation of medicine for treating novel coronal pneumonia
  • Application of umbilical cord mesenchymal stem cells in preparation of medicine for treating novel coronal pneumonia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Before the application of hUMSCs in clinic, the inventors of the present application found that hUMSCs cell culture medium has good immune regulation function.

[0025] Materials and methods:

[0026] Animals: Male C57BL / 6 mice.

[0027] Cells: human umbilical cord mesenchymal stem cells (hUC-MSCs).

[0028] Cell processing method: press 1×10 6 Density The culture solution of hUMSCs cells cultured in a 10 cm dish for 48 hours was filtered through a 0.22 μm filter membrane (Millipore) to remove cells or cell debris, and concentrated 100 times using an ultrafiltration centrifuge tube.

[0029] Acute immune liver injury model production method: 18 male C57BL / 6 mice were divided into 3 groups, the model control group (ConA+PBS), according to 25mg / kg body weight through the tail vein injection of concanavalin dissolved in PBS to induce acute liver injury. After injury, 30 minutes later, inject PBS through the tail vein; the negative control group (PBS+PBS), that is, use P...

Embodiment 2

[0036] hUMSCs after expansion and culture use physiological saline + 1% human serum albumin + 2‰ nadroparin calcium injection to make cell suspension pharmaceutical preparations, and 100mL cell suspension contains 5 × 10 7 mesenchymal stem cells.

[0037] In this embodiment, the cell suspension pharmaceutical preparation is used in critically ill covid19 patients with new coronary pneumonia, and the basic conditions of the patients are as follows:

[0038] After administration, the patient's physical indicators such as Figure 3 ~ Figure 5 shown. Antibiotics are used to prevent infection during treatment, along with thymosin α1. After the first injection, no obvious side effects were observed and the drug was well tolerated. As shown in Table 1, after the second administration, serum bilirubin, CRP, and ALT / AST gradually decreased, and other vital signs improved. From February 13th, the endotracheal tube was also removed and the patient was able to walk on the ground. ...

Embodiment 3

[0049] Isolation and expansion of umbilical cord mesenchymal stem cells and preparation of cell products

[0050] Seed bank primary isolation

[0051] Confirm the donor’s information, medical history, and infectious disease conditions before entering the seed bank (the donor’s HBV, HCV, HIV, and syphilis tests were negative). The isolated umbilical cord has no edema, no folds, and is elastic. Umbilical cord mesenchymal stem cells were cultured to the P2 generation, and a seed bank was established. The cells were cultured with medium MSCPro XenoFree medium (brand: rFib; product number: CCM0016-01).

[0052] The specific operation steps are:

[0053] 1.1 Prepare tissue digestion solution, including collagenase, hyaluronidase, gentamicin sulfate and DEME / F-12;

[0054] 1.2 Take out the umbilical cord, discard the clean umbilical cord blood, separate Wharton’s jelly, and repeatedly cut into pieces of tissue of about 0.5-1mm3 in the collagenase solution for 3 minutes to 15 minut...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of umbilical cord mesenchymal stem cells in preparation of a medicine for treating novel coronal pneumonia. The Corona Virus Disease 2019 is caused by a 2019-nCoV. A human umbilical cord mesenchymal stem cell suspension preparation is used for treating the Corona Virus Disease 2019 through intravenous injection, remarkably reduces the inflammatory factor level in the body of a severe or critical patient, relieves pulmonary edema, effectively relieves the acute respiratory distress syndrome, and reduces the case fatality rate.

Description

technical field [0001] The present invention relates to the field of drugs for the treatment of novel coronavirus pneumonia, in particular to the application of umbilical cord mesenchymal stem cells in the preparation of drugs for the treatment of novel coronavirus pneumonia. Background technique [0002] After 2019-nCoV infection with pneumonia, some patients will develop severe and critical illness, and its pathogenesis is not yet fully understood. It is generally believed that the infection of the body with 2019-nCoV leads to immune dysfunction, especially after the continuous activation of lymphocytes and macrophages, they secrete a large number of cytokines to recruit more immune cells to gather in the lungs to attack the cells infected by the virus. Attacking cell death cleavage products in turn amplify the above responses, leading to cytokine storm syndrome (CSS), which is clinically characterized by systemic inflammation, hyperferritinemia, hemodynamic instability, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/28A61P31/14
CPCA61K35/28A61P31/14
Inventor 胡敏李燕皎马朝霞李涛钱传云曹丽吴兴飞王梦婷马代萍赵云会保鹏飞王思涛梁树
Owner 云南雅盛医疗科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com